Novavax, Inc. (NVAX)
NASDAQ: NVAX · IEX Real-Time Price · USD
17.11
+0.44 (2.64%)
At close: Jul 26, 2024, 4:00 PM
17.07
-0.04 (-0.23%)
After-hours: Jul 26, 2024, 7:59 PM EDT
Novavax Revenue
Novavax had revenue of $93.86M in the quarter ending March 31, 2024, with 15.94% growth. This brings the company's revenue in the last twelve months to $996.61M, down -26.66% year-over-year. In the year 2023, Novavax had annual revenue of $983.71M, down -50.36%.
Revenue (ttm)
$996.61M
Revenue Growth
-26.66%
P/S Ratio
2.41
Revenue / Employee
$645,890
Employees
1,543
Market Cap
2.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.97B |
Patterson Companies | 6.57B |
Amneal Pharmaceuticals | 2.50B |
Premier | 1.34B |
CONMED | 1.26B |
LifeStance Health Group | 1.10B |
Addus HomeCare | 1.09B |
10x Genomics | 625.45M |
NVAX News
- 4 weeks ago - Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine - PRNewsWire
- 6 weeks ago - Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine - PRNewsWire
- 7 weeks ago - My Novavax stock price forecast was correct: what next now? - Invezz
- 7 weeks ago - FDA advisers urge targeting JN.1 strain in fall's COVID vaccines - Market Watch
- 2 months ago - Novavax to Participate in 2024 Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Novavax awaits FDA decision on whether its next COVID shot can be offered in US - Reuters
- 2 months ago - Shah Capital ends campaign against Novavax board after Sanofi deal - Reuters
- 2 months ago - Up 3x In A Week Will Novavax Stock Continue To See Higher Levels? - Forbes